Arizona State Retirement System Decreases Holdings in Thermo Fisher Scientific Inc. $TMO

Arizona State Retirement System decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 106,998 shares of the medical research company’s stock after selling 3,270 shares during the quarter. Arizona State Retirement System’s holdings in Thermo Fisher Scientific were worth $62,000,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of TMO. JPL Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $28,000. Beacon Financial Strategies CORP purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $29,000. Olistico Wealth LLC purchased a new stake in Thermo Fisher Scientific in the 4th quarter valued at approximately $29,000. Cloud Capital Management LLC purchased a new stake in Thermo Fisher Scientific in the 3rd quarter valued at approximately $31,000. Finally, KERR FINANCIAL PLANNING Corp purchased a new stake in Thermo Fisher Scientific in the 3rd quarter valued at approximately $38,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. DZ Bank initiated coverage on Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a “buy” rating and a $610.00 target price on the stock. Stifel Nicolaus upped their target price on Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Wells Fargo & Company set a $683.00 target price on Thermo Fisher Scientific in a research note on Friday, January 30th. Finally, Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $631.25.

Thermo Fisher Scientific Trading Down 9.2%

Shares of Thermo Fisher Scientific stock opened at $466.93 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The firm has a market cap of $173.52 billion, a PE ratio of 26.32, a P/E/G ratio of 2.66 and a beta of 0.97. The business’s fifty day moving average is $499.83 and its two-hundred day moving average is $549.98. The company has a quick ratio of 1.53, a current ratio of 1.89 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The company had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.15 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 24.68 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date was Friday, March 13th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. Thermo Fisher Scientific’s payout ratio is currently 10.60%.

Key Stories Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 results beat consensus on both revenue ($11.01B) and adjusted EPS ($5.44), showing resilience in lab products and biopharma services. Thermo Fisher posts quarterly results beat as lab products, biopharma services grow
• Positive Sentiment: Several analysts reaffirm Buy ratings and call the pullback overdone; TD Cowen reiterated Buy (PT cut) and other firms maintained bullish views citing long-term catalysts (AI in labs, reshoring). Thermo Fisher Scientific: Stock Pullback Seen as Overdone Amid Solid Fundamentals and Second-Half Growth Drivers
• Neutral Sentiment: The company nudged up its FY 2026 outlook overall, but the guidance band showed mixed signals (EPS and revenue targets near or slightly below Street expectations), leaving room for investor disappointment. Thermo Fisher Raises 2026 Outlook Despite First-Quarter Organic Revenue Growth Miss
• Negative Sentiment: Underlying organic growth was softer than investors hoped and management highlighted mixed segment performance (softness in analytical instruments and specialty diagnostics), which pressured sentiment despite the beat. Thermo Fisher falls after earnings top estimates, but growth concerns persist
• Negative Sentiment: Guidance nuances: the EPS range (24.640–25.120) is essentially in line with consensus but slightly uneven vs. expectations, contributing to profit-taking. TMO Q1 Earnings & Revenues Top Estimates, Stock Down in Pre-Market
• Negative Sentiment: Broader market and sector pressure (tech-led sell-off and softer healthcare-group trading) plus geopolitical-driven “modest inflation” risk flagged by management amplified the pullback. Thermo Fisher Flags ‘Modest Inflation’ Risk Amid Middle East Tensions Equities Fall Intraday Amid Tech Sell-Off; Oil Rises

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares in the company, valued at $63,499,170. This represents a 3.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Gianluca Pettiti sold 400 shares of the company’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the sale, the executive vice president owned 20,752 shares of the company’s stock, valued at approximately $11,230,982.40. The trade was a 1.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.